Turkey Company Roundup: Biosimilar Pact, Keytruda Supply, Takeda Deal
This article was originally published in PharmAsia News
TUBITAK (The Scientific and Technological Research Council of Turkey) will produce biosimilars with Nobel Ilac, MSD provides pembrolizumab free to 25 patients in Turkey, Abdi Ibrahim intensifies its R&D efforts, and Takeda purchases a portfolio of new products.
You may also be interested in...
Amid delays in surgical operations caused by shortages of equipment and medtech companies demanding payment of outstanding hospital debts, a strong devaluation of the Turkish lira has put the local health care system on a crisis footing.
Late payment of hospital debts continues to haunt the Turkish medtech industry, which recently led a public demonstration in Ankara to focus the government’s attention on the issue. Medtech multinationals fear that the ongoing problems will mean Turkey losing the positive momentum it achieved during the pandemic.
One Hurdle After Another: Safely Aligned With EU MDR, Turkish Medtechs Brace For New Efforts On Domestic Front
Alignment with the MDR gave Turkish medtech access to the EU market, but in domestic pricing, costs, reimbursement and payment of hospital debts, industry might feel it is barely at the starting line.